Pharmaceutical

NICE expands access of Paxlovid to further 1.4 million Covid-19 patients

Expanded patient groups at risk of progression to severe Covid-19 will be eligible for Pfizer’s antiviral pill.

Jan 11, 2024 - 18:00
NICE expands access of Paxlovid to further 1.4 million Covid-19 patients
Expanded patient groups at risk of progression to severe Covid-19 will be eligible for Pfizer’s antiviral pill.
Read the original article

Tags:

Previous Article

Eli Lilly and Innovent’s obesity drug mazdutide achieves positive Phase III results

Next Article

BridgeBio gears up for FDA review of acoramidis following Phase III results

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: EU poised to reject Amylyx’s ALS drug, as the company vows an appeal

STAT+: EU poised to reject Amylyx’s ALS drug, as the co...

Jun 24, 2023

Chinese NMPA approves Innovent and IASO Bio’s myeloma therapy

Chinese NMPA approves Innovent and IASO Bio’s myeloma t...

Jul 3, 2023

Opinion: Medicare has different standards than the FDA. That’s how it should be

Opinion: Medicare has different standards than the FDA....

Feb 3, 2024